Last verified: April 25, 2026 · Next scheduled review: May 25, 2026 (or sooner after any FDA action)

GLP-1 FDA Approvals Timeline: Every Major Approval From 2005 to 2026

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

This GLP-1 FDA approvals timeline tracks every major FDA milestone from Byetta in 2005 to Foundayo in April 2026 — original drug approvals, expanded indications, new formulations, higher doses, and generics. The headline answers most people want: Byetta (exenatide) was first, approved April 28, 2005 for type 2 diabetes. Saxenda was the first GLP-1 approved for weight loss, December 23, 2014. Rybelsus was the first oral GLP-1, September 20, 2019. Foundayo (orforglipron) is the newest, approved April 1, 2026.

Factual focus: FDA milestone approvals only. Verify current availability and prescribing information before treatment decisions.

The complete GLP-1 FDA approvals timeline (2005–2026)

Landmark rows highlighted in amber. That’s the whole class, in order.

What was the first FDA-approved GLP-1 medication?

That single 2005 approval is why “the GLP-1 class is 21 years old” is true in 2026. It also explains why the conversation around GLP-1s is much older than the Ozempic moment most people think of as the start.

The early years were quiet. Byetta sold modestly. Bydureon — a once-weekly extended-release version of the same molecule — launched in 2012. Victoza (liraglutide) arrived in 2010 as a daily injection. None of these became cultural events. They were diabetes drugs that helped lower A1C and produced modest weight loss as a side effect. The “side effect” part is what eventually changed everything.

What is the newest FDA-approved GLP-1?

Foundayo is also a regulatory landmark. It’s the first new molecular entity approved under the FDA’s new Commissioner’s National Priority Voucher (CNPV) pilot program — the agency cleared it in just 50 days after filing, the fastest NME approval since 2002.

If you’ve been hearing about Foundayo and wondering whether it’s actually FDA-approved or one of those compounded products with a clever brand name, the answer is: fully FDA-approved, available now.

Which GLP-1 drugs are FDA-approved and still being marketed?

Note on generics: FDA approval of a generic does not automatically mean it’s stocked at every pharmacy. Verify availability with your specific pharmacy.

Which GLP-1 drugs are FDA-approved for weight loss?

Which GLP-1 drugs are FDA-approved for type 2 diabetes?

Which oral GLP-1 medications are FDA-approved?

Why the difference? Rybelsus and the Wegovy pill both contain semaglutide, a peptide molecule. Peptides are destroyed by stomach acid, so Novo Nordisk uses SNAC technology to protect the peptide in a specific empty-stomach window. Foundayo is a non-peptide small molecule — it doesn’t have the same absorption challenge, so it can be taken any time of day.

What major label expansions has the FDA approved for GLP-1 drugs?

The four eras of GLP-1 FDA approvals

Era 4 has produced more major FDA actions involving GLP-1s — ten in 18 months — than Eras 1, 2, and 3 each produced individually. The drugs are no longer “diabetes drugs that also help with weight.” They’re metabolic-axis drugs with a growing list of organ-system indications, and the FDA’s new CNPV program is clearing them in 50–54 days instead of 10–12 months.

Are compounded GLP-1 medications FDA-approved?

Here’s the current regulatory snapshot on compounded GLP-1s:

If a website presents a compounded product as equivalent to Ozempic or Wegovy, treat that as marketing language — the FDA does not certify equivalence between approved drugs and compounded versions.

If regulatory certainty matters to you — a drug the FDA has reviewed, manufactured to FDA standards, with a known label — choose an FDA-approved option. If price is your top priority, see our compounded GLP-1 provider guide for honest comparisons.

One thing this page won’t do for you

We’re not going to tell you which GLP-1 you should take. We can show you what’s been FDA-approved and when — that part is verifiable from primary sources, and we’ve cited every row. But your actual fit depends on diagnosis, BMI, contraindications, current medications, insurance, state availability, and clinician judgment. A regulatory timeline doesn’t cover any of that.

Why some GLP-1 approval timelines disagree

Our master table tags every row by approval type for that reason — original drug approval, expanded indication, new formulation or dose, or generic.

Generics, withdrawals, and discontinuations

If you’ve heard someone ask “is there a generic Ozempic yet?” — the answer is no. The generics that exist today are for the older drugs in the class. If you’ve wondered why Tanzeum disappeared — GSK pulled it from the market in 2018 for commercial reasons, not safety problems. Same story with Adlyxin and the AstraZeneca exenatide products.

How to actually access an FDA-approved GLP-1 today

Through your primary care doctor + insurance

Best when you have commercial insurance with GLP-1 coverage and your doctor is comfortable prescribing. Most commercial plans require prior authorization for branded GLP-1s — paperwork your provider’s office files demonstrating medical necessity. Prior auth approval takes 24 hours to several weeks.

In KFF’s analysis of 2024 Marketplace plan data, Wegovy was covered by just 1% of Marketplace prescription drug plans for weight loss. Coverage is broader for diabetes-indicated GLP-1s and for cardiovascular and CKD indications.

Through a telehealth provider

Telehealth is a major access path in 2026, especially for weight-loss-indicated drugs that traditional insurance won’t cover for many adults.

• Ro — Carries Foundayo, the Wegovy pill, Wegovy pen, Wegovy HD, Zepbound pen, Zepbound KwikPen, and Ozempic. Free GLP-1 Insurance Coverage Checker. Insurance concierge for many commercial plans (not government plans except FEHB). Ro Body membership: $39 first month, then $149/month or as low as $74/month with annual prepay. Medication cost is separate.
• Sesame Care — Foundayo, Wegovy pill, Wegovy injection, Zepbound (pen, KwikPen, and vial), and Ozempic. Per-visit pricing, no membership. Strong for comparing across multiple medications.

Last verified April 25, 2026.

Direct from the manufacturer

LillyDirect sells Foundayo, Zepbound (multiple formulations), and Mounjaro directly to patients with a prescription. NovoCare sells the Wegovy pill, Wegovy injection (2.4 mg and 7.2 mg HD), and Ozempic. Both publish cash-pay pricing and integrate with major retail pharmacies. Direct-from-manufacturer is usually the cleanest cash-pay path.

Provider snapshot (verified April 25, 2026)

What’s coming next for GLP-1 FDA approvals?

For the full trial-by-trial breakdown, see our GLP-1 clinical trials tracker.

First-in-class moments worth knowing

Before you close this tab, here’s the honor roll — the GLP-1 approvals that meaningfully changed the field.

Fifteen “firsts” in 21 years. That’s why this is the most consequential drug class of the century so far.

Frequently asked questions

Still figuring out which path is right for you?

If you’ve read this far, you know more about GLP-1 FDA approvals than 99% of patients walking into a primary care visit. Here’s how to convert that into action.

If you’re researching for someone else: Bookmark this page. We update it monthly and after every FDA action involving a GLP-1.

Methodology

We built this page from the FDA’s official press announcements at FDA.gov, Drugs@FDA approval letters and current prescribing information for every active drug in the class, manufacturer press releases at the time of approval, and the Drugs.com FDA Approval History database. Where dates conflicted across sources, we deferred to the FDA primary source. Every clinical claim about a specific drug’s approved indication is drawn from that drug’s current FDA-approved prescribing information, not from secondary summaries.

We did not use Reddit, social media, forums, or affiliate provider claims as evidence for any regulatory or clinical statement. We read those sources to understand how readers phrase their questions — that informed the FAQ structure, but not the facts.

Correction policy: If you spot something that looks wrong, email corrections@therxindex.com with the FDA source — we’ll re-verify within 48 hours. We’d rather be right than fast.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. FDA approval status, label indications, and drug availability can change. Always verify current prescribing information and discuss treatment decisions with your licensed prescribing clinician.